Bright Minds Biosciences (Bright Minds Biosciences) Net Cash per Share : $0.84 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Bright Minds Biosciences's Net Cash per Share for the quarter that ended in Mar. 2024 was $0.84.

The historical rank and industry rank for Bright Minds Biosciences's Net Cash per Share or its related term are showing as below:

DRUG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.26 Med: 2.04 Max: 5.59
Current: 1.4

During the past 4 years, the highest Price-to-Net-Cash Ratio of Bright Minds Biosciences was 5.59. The lowest was 1.26. And the median was 2.04.

DRUG's Price-to-Net-Cash is ranked better than
81.87% of 855 companies
in the Biotechnology industry
Industry Median: 4.05 vs DRUG: 1.40

Bright Minds Biosciences Net Cash per Share Historical Data

The historical data trend for Bright Minds Biosciences's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Net Cash per Share Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Net Cash per Share

0.38

6.38

2.15

1.27

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial													1.69	1.48	1.27	0.99	0.84

Competitive Comparison of Bright Minds Biosciences's Net Cash per Share

For the Biotechnology subindustry, Bright Minds Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Price-to-Net-Cash falls into.

Bright Minds Biosciences Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Bright Minds Biosciences's Net Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as

	Net Cash per Share (A: Sep. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.987	-	0.208	-	0)	/	3.77207
=	1.27

Bright Minds Biosciences's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.382	-	0.625	-	0)	/	4.46384
=	0.84

Bright Minds Biosciences (NAS:DRUG) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Bright Minds Biosciences Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.